Reasons for this failure may range from differences in the patient cohort to incomplete inhibition calling for a better understanding of the complex function and regulation of IDO1 in the tumor and its microenvironment (TME) [55, 57, 58]. The gene discussed is IDO1; the disease is neoplasm.